PDCD1 and cancer: For the treatment of cancers, the US Food and Drug Administration (FDA) has approved PD-1 inhibitors (nivolumab, pembrolizumab, and cemiplimab), PDL-1 inhibitors (atezolizumab, durvalumab, and avelumab), and CTLA-4 inhibitors (ipilimumab) [144].